Opticeuticals: A Category, Defined and Published

Effective today, Atumnus Life Sciences publishes the formal definition, naming, and category authority for a new tier of consumer-facing supplementation. The category is named Opticeuticals — optimized nutraceuticals — and it is positioned as the fourth stage in the long evolution of human supplementation: from food, to vitamins, to nutraceuticals, to opticeuticals.

The category exists because the existing supplement designations no longer describe what is now possible. Vitamin science was settled in the early twentieth century. The nutraceutical designation was introduced by Stephen DeFelice in 1989 to describe products that bridged food and pharmaceutical effect. In the thirty-seven years since, the nutraceutical category has expanded to include essentially any dietary supplement, regardless of mechanism, dose, or manufacturing discipline. The word itself has lost the inference that DeFelice intended it to carry.

The working definition

“An Opticeutical is an optimized nutraceutical — a product meeting a defined standard for peptide-class bioregulator formulation, sourcing integrity, evidence orientation, and cGMP manufacturing discipline.”

The full text of the working definition, with the six-pillar standard that operationalises it, is published in detail at the standard reference. The short form above is the canonical working definition. A product is or is not an Opticeutical depending on whether it meets all six pillars. Partial qualification does not exist. Qualification is granted on a per-product, per-batch basis by Atumnus Life Sciences as the category steward.

Why a fourth stage was necessary

Three converging developments made a new category designation appropriate. First, the peptide-class bioregulator research lineage — four decades, eight hundred publications, centred at Saint Petersburg and now distributed across collaborating institutions — produced a body of consumer-applicable science that the existing supplement categories cannot accommodate. The mechanism is regulatory rather than nutritional. The dose-response curve is conservative. The evidence required to support a claim is different in kind from anything that vitamin or nutraceutical regulation contemplated.

Second, the longevity and anti-aging consumer category — built originally around nutraceutical and vitamin-derivative products such as NAD+ precursors, senolytics, and sirtuin activators — encountered the ceiling that mechanism-naive supplementation reaches in every era. Substantial consumer demand exists for products that act on the molecular biology of aging. The supplement category as currently constituted cannot reliably deliver them.

Third, the supplement industry's quality variance — documented at length in the published research on contamination, label-claim failure, and identity adulteration — produced a credibility deficit that the industry has not been able to close from within. A category-level standard, applied uniformly and verified independently, is the mechanism by which a more disciplined tier becomes recognisable.

What Opticeuticals is, and is not

Opticeuticals is a consumer supplement category. It is not a pharmaceutical category, not a medical-device category, and not a prescription category. Opticeutical products are intended to be available over-the-counter, subject to the same dietary-supplement framework that DSHEA 1994 established, with discipline added rather than substituted.

Opticeuticals are not a brand of supplement. The Opticeutical name is a category designation, like nutraceutical or pharmaceutical. Individual brands and individual products will qualify under the standard or not. Multiple manufacturers, formulators, and brand owners will produce Opticeutical-qualified products over time. Atumnus Life Sciences serves as the steward of the category and the holder of the underlying compound and platform IP, but does not occupy the category itself as a single brand.

What is published today

• The formal definition of an Opticeutical, with the six-pillar standard governing qualification.
• The four-stage evolution from food to vitamins to nutraceuticals to opticeuticals.
• The scientific foundation in peptide-class bioregulator research, with citations to the institutional reference at endogenicpharmacology.com.
• The trade-named delivery platform portfolio and the Opti-Salt™ therapeutic salt carrier system.
• The position of Atumnus Life Sciences as the category steward.

What follows

Over the coming months, Atumnus will publish the final form of the Opticeutical Standard with full implementation guidance, name the first qualified manufacturing and verification partners, announce the founding scientific advisory, and begin moving specific products into the marketplace under the standard. Each substantive milestone will be documented in this newsroom. Each will be cross-referenced to the underlying science and to the institutional reference where the discipline of endogenic pharmacology is treated in depth.

Today's publication is the formal opening of the category. The work behind it has taken four years. The reading of it should take less.